The comparative efficacy of intramuscular antipsychotics for the management of acute agitation

被引：9

作者：

Bosanac, Peter ^{[1
]}

Hollander, Yitzchak ^{[2
]}

Castle, David ^{[3
,4
]}

机构：

[1] St Vincents Mental Hlth Serv, Clin Serv, Melbourne, Vic, Australia

[2] Alfred Psychiat, Acute Unit, Melbourne, Vic, Australia

[3] St Vincents Hosp, Fitzroy, Vic 3065, Australia

[4] Univ Melbourne, Fitzroy, Vic 3065, Australia

来源：

AUSTRALASIAN PSYCHIATRY | 2013年 / 21卷 / 06期

关键词：

acute agitation; antipsychotics; atypical antipsychotics; efficacy; haloperidol; intramuscular; DOUBLE-BLIND; SCHIZOAFFECTIVE DISORDER; HALOPERIDOL; OLANZAPINE; ZIPRASIDONE; SCHIZOPHRENIA; PLACEBO; ARIPIPRAZOLE; TOLERABILITY; EXACERBATION;

D O I：

10.1177/1039856213499620

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Objective: To review the current role and comparative efficacy of short-acting intramuscular (IM) antipsychotics in the management of acute agitation, in current clinical practice. Method: The efficacy and tolerability of IM antipsychotics in the management of acute agitation in current clinical practice were reviewed in the Medline, PubMed, Cinahl Plus, Scopus-v.4 and PsycInfo databases. Results: The comparative efficacy of the rapidly-acting IM atypical antipsychotics (olanzapine, ziprasidone and aripiprazole) is similar to that of the typical antipsychotic, haloperidol. IM olanzapine and ziprasidone were associated with fewer extrapyramidal side-effects and had similar cardiac tolerability to IM haloperidol. Conclusions: Further studies are required in the ongoing development of contemporary, evidence-based clinical guidelines in acute agitation, including head-to-head comparisons of currently utilized IM atypical antipsychotics, sequential treatment or combinations of medications.

引用

页码：554 / 562

页数：9

共 55 条

[1]

Abdelmawla N., 2006, Advances in Psychiatric Treatment, V12, P35, DOI [10.1192/apt.12.1.35, DOI 10.1192/APT.12.35]

[2] Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders [J].

Agid, Ofer ;

Kapur, Shitij ;

Warrington, Lewis ;

Loebel, Antony ;

Siu, Cynthia .

SCHIZOPHRENIA RESEARCH, 2008, 102 (1-3) :241-248

[3]

Allen Michael H, 2003, J Psychiatr Pract, V9, P39

[4] Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol [J].

Andrezina, Raisa ;

Josiassen, Richard C. ;

Marcus, Ronald N. ;

Oren, Dan A. ;

Manos, George ;

Stock, Elyse ;

Carson, William H. ;

Iwamoto, Taro .

PSYCHOPHARMACOLOGY, 2006, 188 (03) :281-292

[5]

[Anonymous], J PSYCHIAT PRACT

[6] Pharmacological management of acute agitation [J].

Battaglia, J .

DRUGS, 2005, 65 (09) :1207-1222

[7] Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study [J].

Battaglia, J ;

Moss, S ;

Rush, J ;

Kang, J ;

Mendoza, R ;

Leedom, L ;

Dubin, W ;

McGlynn, C ;

Goodman, L .

AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1997, 15 (04) :335-340

[8]

Bergstrom RF, 2004, J EMERG NURS, V30, P417

[9] A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia [J].

Breier, A ;

Meehan, K ;

Birkett, M ;

David, S ;

Ferchland, I ;

Sutton, V ;

Taylor, CC ;

Palmer, R ;

Dossenbach, M ;

Kiesler, G ;

Brook, S ;

Wright, P .

ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (05) :441-448

[10] Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study [J].

Brook, S ;

Walden, J ;

Benattia, I ;

Siu, CO ;

Romano, SJ .

PSYCHOPHARMACOLOGY, 2005, 178 (04) :514-523

← 1 2 3 4 5 6 →